COVID-19 vaccine - Quiz
A) Reducing mutation rates of the virus B) Preventing symptomatic, often severe, illness C) Eradicating the virus globally D) Preventing all transmission
A) Soberana B) Janssen C) Razi Cov Pars D) Pfizer–BioNTech
A) Spike protein B) Envelope protein C) Membrane protein D) Nucleocapsid protein
A) They completely block viral entry B) They are easier to manufacture C) They induce a robust T-cell response D) They have no genomic variability
A) Locking the spike protein into its prefusion configuration B) Creating a live attenuated virus C) Preventing lipid degradation D) Increasing the speed of mRNA production
A) Injected directly into cell nuclei B) Encapsulated in lipid nanoparticles C) Attached to viral vectors D) Mixed with attenuated live virus
A) CVnCoV B) Spikevax C) Comirnaty D) Mnexspike
A) The nucleoside modifications B) The preservative agents C) Lipid nanoparticles D) The mRNA strands
A) Spikevax B) Mnexspike C) Comirnaty D) Convidecia
A) Exactly three B) At least nine C) Twelve D) Only two
A) January 2021 B) December 2019 C) March 2020 D) August 2020
A) Pfizer and BioNTech B) Moderna and Novavax C) Katalin Karikó and Drew Weissman D) The World Health Organization
A) It wanes B) It becomes permanent C) It increases D) It disappears immediately
A) No B) Only after weaning C) Yes D) Only with medical supervision
A) 5 to 10 million B) 20 to 25 million C) 1 to 3 million D) 14.4 to 19.8 million
A) Autoimmune disease B) Permanent paralysis C) Chronic organ failure D) Myalgia
A) Over 13 billion B) Under 5 billion C) Over 50 billion D) Exactly 10 billion
A) Zika research B) SARS and MERS research C) Ebola research D) Influenza research
A) To cure long COVID B) To act as a treatment for infected individuals C) To serve as booster doses D) To replace initial vaccines entirely
A) The elderly and healthcare workers B) Only government officials C) Children and students D) The wealthiest citizens
A) A few months B) Over two decades C) Several years D) Less than one year
A) Feline coronavirus B) Porcine circovirus C) Equine influenza D) Bovine rotavirus
A) Two were approved for MERS B) None existed C) Several were widely used D) One was approved for SARS
A) Approved in 2006 B) Approved in 2020 C) Approved in 2005 D) None exists
A) Three B) Zero C) One D) Five
A) mRNA-based B) Live attenuated C) Inactive virus D) DNA-based
A) Less than one year B) Two to three years C) More than a decade D) Six months
A) 2010 B) 2015 C) 2020 D) 2005
A) MERS B) Ebola C) SARS D) Influenza
A) Birds only B) Non-human animals C) Humans only D) Primates only
A) Inactivated virus B) mRNA-based C) Viral-vectored D) Protein subunit
A) Rhinovirus B) Adenovirus C) Influenza virus D) Coronavirus
A) By producing an antigen via encoded DNA B) By transferring mRNA directly to the nucleus C) By injecting live coronavirus D) By using heat-killed viral particles
A) Ad2 B) Ad10 C) Ad5 D) Ad26
A) By removing their DNA B) By heat or formaldehyde C) By coating them in protein subunits D) By freezing them in liquid nitrogen
A) CoronaVac B) Novavax C) Convidecia D) ZF2001
A) By heat-inactivation of SARS-CoV-2 B) By chemical synthesis of proteins C) By infecting moth cells with a modified baculovirus D) By using cultured adenovirus
A) Protein antigens B) Spike proteins C) A lipid membrane D) RNA or DNA
A) Bimervax B) QazVac C) Sputnik V D) Covaxin
A) 10 B) 50 C) 25 D) 100
A) Razi Cov Pars B) BCG vaccine C) Pneucolin D) Sputnik V
A) IgE B) IgG C) IgM D) IgA
A) China B) Iran C) India D) Russia
A) Intranasal spray B) Intramuscular injection C) Oral administration D) Intravenous infusion
A) 2025 B) 2022 C) 2026 D) 2024
A) Faster manufacturing time B) Requirement for fewer doses C) Higher viral load suppression D) Ease of administration without needles
A) Innate cellular immunity B) Systemic immunity C) Passive immunity D) Mucosal immunity
A) The first viral component of Sputnik V B) Razi Cov Pars C) Pneucolin D) iNCOVACC
A) India B) Iran C) USA D) China
A) March 2022 B) April 2022 C) May 2024 D) June 2025
A) China B) France C) Canada D) UK
A) Focusing on pediatric populations B) Targeting the receptor-binding domain C) Targeting the entire viral genome D) Targeting only the nasal cavity
A) European Medicines Agency B) White House C) Chinese Center for Disease Control D) Walter Reed Army Institute of Research
A) Overabundance of funding B) Governmental bans on science C) Physical distancing D) Lack of interest
A) International borders are closed to research B) Changing transmission rates make the virus a 'moving target' C) The vaccines are too expensive D) Participants prefer placebo groups
A) Operation Warp Speed B) R&D Blueprint C) Vaccine Bank D) COVAX
A) Diagnostics B) Therapeutics C) Manufacturing D) Health Systems Connector
A) Developing medical school curricula B) Funding disease-fighting technology C) Regulating drug safety laws D) Managing global vaccine distribution
A) Operation Warp Speed B) ACT-Accelerator C) The Vaccine Bank D) The R&D Blueprint
A) Novavax B) Johnson & Johnson C) Moderna D) Pfizer
A) Environmental surfaces B) Mild infections C) Severe infections D) Asymptomatic carriers only
A) Around 77% B) Around 26% C) Around 95% D) Around 50%
A) 50% B) 26% C) 77% D) 90%
A) Boosters B) Wait times C) Placebos D) Therapeutics
A) Red Cross B) Doctors Without Borders C) United Nations D) World Health Organization
A) Individual protection titers are determined by weight B) Individual protection titers remain unknown C) Individual protection titers are clearly defined D) Individual protection titers are not associated with immunity
A) Every month B) Every two years C) Every six months D) Once per lifetime
A) 19% B) 90% C) 43% D) 70%
A) Case reports only B) Observational studies C) Computer simulations D) Randomized clinical trials
A) No B) Yes, but only in the Moderna trials C) Yes, in all of them D) Yes, but only in the Pfizer trials
A) Heterologous vaccination B) Standard regimen C) Single-dose regimen D) Homologous vaccination
A) The risks from the vaccine are higher. B) There is no way to compare the risks. C) The risks are about the same. D) The risks from COVID-19 are far higher.
A) Allergic reaction. B) Intramuscular trauma. C) Nocebo effect. D) Inflammation.
A) 55. B) 2,700. C) 250. D) 17.
A) Infants. B) People with chronic illness only. C) Older people. D) Younger people.
A) 11.6%. B) 20%. C) 5%. D) 16%.
A) One year. B) Two menstrual cycles. C) One week. D) Six months.
A) mRNA vaccines. B) Vector vaccines. C) Inactivated vaccines. D) DNA vaccines.
A) 73. B) 9. C) 31. D) 250.
A) 0.5% B) 5% C) 1.07% D) 0.015%
A) Immunocompromised individuals B) Young males C) Elderly females D) Children under 5
A) VigiBase B) CoWIN C) EudraVigilance D) Aarogya Setu
A) Supports waiving intellectual property protections B) Supports stricter patent enforcement C) Proposed a ban on foreign vaccine exports D) Remains neutral on the issue
A) Countries with low tourism rates. B) Poor countries. C) Rich countries. D) Countries with no vaccine supply.
A) Rich countries. B) Countries in the northern hemisphere. C) Island nations. D) Poor countries.
A) Demand significantly exceeded supply. B) Vaccines were readily available for everyone. C) Supply significantly exceeded demand. D) There was no interest in getting vaccinated.
A) The state health department. B) High school students only. C) Mukesh Aggarwal. D) A group of pharmacy owners.
A) @VaccineHunter B) @BayVaccine C) @CovaxSF D) @CVSBot
A) MyTurn. B) VaccineAlert. C) GlobalVaccineTracker. D) HealthPortal.
A) The developers lost interest B) The websites were hacked by competitors C) The need for intensive monitoring declined D) They were banned by federal law
A) Open-source scripts B) Telephone hotlines C) Official government apps D) Physical paper maps
A) New York B) Florida C) Texas D) California
A) Alex Azar B) Ron DeSantis C) Joe Biden D) Donald Trump
A) Willful misconduct B) Negligence C) Product spoilage D) High pricing
A) France B) Argentina C) United Kingdom D) Brazil
A) Standard authorization B) Liability exemption C) Conditional marketing authorization D) Emergency use permit
A) December 2020 B) September 2022 C) February 2020 D) November 2023
A) A congressional hearing B) A Supreme Court trial C) An international tribunal D) A grand jury
A) Public Health Emergency Act B) Consumer Vaccine Safety Act C) Texas Deceptive Trade Practices Act D) PREP Act
A) Philippines B) China C) United States D) Saudi Arabia |
Created with That Quiz —
the site for test creation and grading in math and other subjects.